Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 20/20 | 0.62 |
| ▸ | CDK9 | P50750 | 4/20 | 0.62 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509955 | 0.93 | CDC7 (0.63) | CDC7CDK9PRKCBCDK2MAPK1 | |
| SCHEMBL4504342 | 0.92 | CDC7 (0.61) | CDC7CDK9PRKCBCDK2MAPK1 | |
| SCHEMBL5483894 | 0.90 | CDC7 (0.63) | CDC7CDK9PRKCBCDK2MAPK1 | |
| SCHEMBL5483896 | 0.90 | CDC7 (0.63) | CDC7CDK9PRKCBCDK2MAPK1 | |
| SCHEMBL5461008 | 0.85 | CDC7 (0.66) | CDC7CDK9PRKCBCDK2MAPK1 | |
| SCHEMBL5481089 | 0.83 | CDC7 (0.62) | CDC7CDK9 | |
| SCHEMBL5481095 | 0.83 | CDC7 (0.62) | CDC7CDK9 | |
| SCHEMBL5467300 | 0.82 | CDC7 (0.61) | CDC7CDK9PRKCBCDK2MAPK1 | |
| SCHEMBL4507524 | 0.82 | CDC7 (0.60) | CDC7CDK9PRKCBCDK2MAPK1 | |
| SCHEMBL5467305 | 0.81 | CDC7 (0.60) | CDC7CDK9PRKCBCDK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | CDC7 359/4885CDK9 48/4885PRKCB 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.